Martin Zentgraf
Directeur Général chez Desitin Arzneimittel GmbH
Profil
Martin Zentgraf currently works at Desitin Arzneimittel GmbH, as Managing Director and Bourne Capital Partners LLC (Private Equity), as Senior Advisor from 2022.
Dr. Zentgraf received his graduate degree in 1985 from the University of Münster.
Postes actifs de Martin Zentgraf
| Sociétés | Poste | Début |
|---|---|---|
Desitin Arzneimittel GmbH
 Desitin Arzneimittel GmbH Pharmaceuticals: MajorHealth Technology Desitin Arzneimittel GmbH manufactures pharmaceutical products for neurological and psychiatric illnesses. Its products are geared towards the treatment of epilepsy, migraine and Parkinson's disease. The company was founded in 1919 and is headquartered in Hamburg, Germany. | Directeur Général | 10/10/2011 |
Bourne Capital Partners LLC (Private Equity)
 Bourne Capital Partners LLC (Private Equity) Investment ManagersFinance Bourne Capital Partners LLC (Bourne Partners) is a private equity firm founded in 2001 by Banks Bourne. The firm is headquartered in Charlotte, North Carolina. | Consultant / Advisor | 01/01/2022 |
Formation de Martin Zentgraf
| University of Münster | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Desitin Arzneimittel GmbH
Desitin Arzneimittel GmbH Pharmaceuticals: MajorHealth Technology Desitin Arzneimittel GmbH manufactures pharmaceutical products for neurological and psychiatric illnesses. Its products are geared towards the treatment of epilepsy, migraine and Parkinson's disease. The company was founded in 1919 and is headquartered in Hamburg, Germany. | Health Technology |
Bourne Capital Partners LLC (Private Equity)
Bourne Capital Partners LLC (Private Equity) Investment ManagersFinance Bourne Capital Partners LLC (Bourne Partners) is a private equity firm founded in 2001 by Banks Bourne. The firm is headquartered in Charlotte, North Carolina. | Finance |
